Expertise in
36
conditions

Dr. Andreas Klein

Hematology
Tufts Medical Center Cancer Center
860 Washington St Bldg 8, 
Boston, MA 
Accepting New Patients
31 Years of Experience
Expertise in
36
conditions
Tufts Medical Center Cancer Center
860 Washington St Bldg 8, 
Boston, MA 

Overview

Andreas Klein is a Hematologist in Boston, Massachusetts. Dr. Klein has been practicing medicine for over 31 years is highly rated in 36 conditions, according to our data. His top areas of expertise are Burkitt Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Klein is currently accepting new patients.

His clinical research consists of co-authoring 37 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in MA

Hospital Affiliations

Tufts Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
First Medical Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Tufts Medical Center Cancer Center
860 Washington St Bldg 8, Boston, MA 02111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Phase 1 Study of PBCAR19B in Participants With CD19-expressing Malignancies
A Phase 1 Study of PBCAR19B in Participants With CD19-expressing Malignancies
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Genetic
Study Phase: Phase 1
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen
Enrollment Status: Unknown
Publish Date: February 21, 2022
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Etoposide, Ixazomib Citrate, Methotrexate, Prednisone, Rituximab, Therapeutic Hydrocortisone, Vincristine Sulfate
Study Phase: Phase 1/Phase 2
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

37 Total Publications

Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure.
Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure.
Journal: Leukemia & lymphoma
Published: April 08, 2025
Similar Doctors
Expertise in
18
conditions
Dr. Raymond Comenzo
Hematology
Expertise in
18
conditions
Dr. Raymond Comenzo
Hematology

Tufts Medical Center Cancer Center

860 Washington St Bldg 8, 
Boston, MA 
 (0.2 miles away)
617-263-8312
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Raymond Comenzo is a Hematologist in Boston, Massachusetts. Dr. Comenzo is highly rated in 18 conditions, according to our data. His top areas of expertise are Primary Amyloidosis, Multiple Myeloma, Cardiac Amyloidosis, Bone Marrow Transplant, and Tissue Biopsy. Dr. Comenzo is currently accepting new patients.

Expertise in
42
conditions
Dr. David Kuter
Hematology
Expertise in
42
conditions
Dr. David Kuter
Hematology

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (0.9 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Kuter is a Hematologist in Boston, Massachusetts. Dr. Kuter is highly rated in 42 conditions, according to our data. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Thrombocytopenia, Autoimmune Hemolytic Anemia, and Splenectomy.

Expertise in
11
conditions
Dr. Steven Dubois
Hematology | Oncology
Expertise in
11
conditions
Dr. Steven Dubois
Hematology | Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (2.4 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances

Steven Dubois is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Dubois is highly rated in 11 conditions, according to our data. His top areas of expertise are Ewing Sarcoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Osteosarcoma.

Frequently Asked Questions about Dr. Andreas Klein

How do I make an appointment with Dr. Andreas Klein?

You can book an appointment with Dr. Andreas Klein by calling their office at 617-263-8312. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Andreas Klein a top-rated expert for Burkitt Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Andreas Klein is classified as an Elite expert for Burkitt Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Andreas Klein specialize in?

While Dr. Andreas Klein is a Hematology, they have specific expertise in Burkitt Lymphoma, Non-Hodgkin Lymphoma, and Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Andreas Klein participate in research or clinical trials?

Yes. Dr. Andreas Klein has published 37 articles and abstracts on conditions like Burkitt Lymphoma. You can view a list of Dr. Andreas Klein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Andreas Klein accept my insurance?

Dr. Andreas Klein accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-263-8312 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Klein's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 24 Advanced Conditions
View All 65 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile